Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Jane Smith, deputy editor
  1. jsmith{at}bmj.com

    We might look back on the 2000s and see them as the time when medical education really did begin to lose its dependence on drug company funding. A cluster of articles in this week’s issue suggests a groundswell of change from around the world.

    In the United States the Macy report, published earlier this year, recommends that organisations providing accredited continuing medical education should stop receiving funds from drug and device companies. Suzanne Fletcher, who chaired the committee that wrote the report, acknowledges that this process will probably take several years and “will also take professional leadership” (doi: 10.1136/bmj.a1023). Although the recommendation was made on ethical grounds, she …

    Access to the full text of this article requires a subscription or payment

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    THIS WEEK'S POLL